Skip to main content
Lynda Chin

Lynda Chin, MD

CEO, Apricity Health
United States
Dr. Chin is an elected member of the National Academy of Medicine, a renowned cancer genomic scientist and a leader in application of technologies, AI/ML and big data in medicine. A dermatologist by training, Dr. Chin began her research career in cancer genomics and cancer biology at the Dana Farber Cancer Institute and Harvard Medical School, and at the Broad Institute. She was actively involved in and served on the executive subcommittee of The Cancer Genome Atlas (TCGA). As the founding chair of the first ever Department of Genomic Medicine at MD Anderson Cancer Center, she launched initiatives to develop technology-enabled platform capabilities to accelerate translation of genomic science into evidence-based care. Throughout her career, Dr. Chin has championed integration and collaboration between the research and clinical care enterprises, and across academia and industry to accelerate precision therapeutic development. She was the scientific director at the Belfer Applied Cancer Institute of Dana-Farber Cancer Institute and later at the Institute for Applied Cancer Science of MD Anderson Cancer Center, both built on a novel organizational construct designed to bridge across research, clinical care and biotechnology to accelerate science-based data-driven drug discovery.

Double Helix


Supporting Bank Sponsor


Premier Sponsors

Conference Sponsors


Media Partner


Sign up for updates

Stay up-to-date on the BIO CEO and Investor Conference via email.